BRIC Expenditures Increasing at a Much Faster Pace than US
IMS Health
Clinical subject expenditures are sizable and represent an average of 5% of per-patient budget of later phase clinical trials. Relative subject reimbursement costs can play a large role in which region to select.
IMS Health maintains current data on relative costs of clinical subject reimbursements around the world in the GrantPlan database, which contains the clinical investigator grants for sponsor companies and CROs that conduct over three quarters of all commercial clinical trials.
Current analysis demonstrates the reimbursement per subject in these emerging geographies is growing more rapidly than in the more established US region. The United States has been averaging 8% annual expense increases and ~1% stipend increase from 2011-2013, while reimbursement costs in BRIC countries (Brazil, Russia, India, and China) are growing at two times those rates, with ~20% expense increase and 17% stipend increase. Russia is by far the highest increase. Even if BRIC countries are starting off on a lower base compared to the US, the rapid rise in cost in these regions warrant our careful consideration in the coming years.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
